{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T04:18:59Z","timestamp":1766290739922,"version":"3.37.3"},"reference-count":50,"publisher":"Endocrinology Research Centre","issue":"2","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Currently, all pheochromocytoma\/paraganglioma (PPGLs) are considered malignant due to metastatic potential. Consequently, PPGLs are divided into \u00abmetastatic\u00bb and \u00abnon-metastatic\u00bb. Metastatic PPGLs can be with synchronous metastasis (metastases appear simultaneously with the identified primary tumor) or metachronous (metastases develop after removal of the primary tumor). The term metastatic PPGLs is not used in the presence of tumor invasion into surrounding organs and tissues, without the presence of distant metastases of lymphogenic or hematogenic origin. It is generally believed that about 10% of pheochromocytomas and about 40% of sympathetic paragangliomas have metastatic potential. On average, the prevalence of PPGLs with the presence of metastases is 15\u201320%. Risk factors for metastatic PPGLs are widely discussed in the literature, the most significant of which are groups of clinical, morphological and genetic characteristics. The review presents a discussion of such risk factors for metastatic PPGLs as age, localization and type of hormonal secretion of the tumor, the size and growth pattern of the adrenal lesion, the presence of necrosis and invasion into the vessels, the tumor capsule surrounding adipose tissue, high cellular and mitotic activity, Ki-67 index, expression of chromogranin B and S100 protein, the presence of genetic mutations of three main clusters (pseudohypoxia, kinase signaling and Wnt signaling).<\/jats:p><jats:p>Over the past two decades, a number of authors have proposed various predictor factors and scales for assessing a probability of metastatic PPGLs. The review contains detailed description and comparison of sensitivity and specificity of such predictor scales as PASS, GAPP, M-GAPP, ASES and COPPS.<\/jats:p>","DOI":"10.14341\/probl13331","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:18:14Z","timestamp":1716391094000},"page":"37-45","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":1,"title":["Metastatic risk factors in  pheochromocytoma\/paraganglioma"],"prefix":"10.14341","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-4174","authenticated-orcid":true,"given":"D. V.","family":"Rebrova","sequence":"first","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-4895","authenticated-orcid":true,"given":"O. I.","family":"Loginova","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-9069","authenticated-orcid":true,"given":"S. L.","family":"Vorobyev","sequence":"additional","affiliation":[{"name":"National Clinical Center of Morphological Diagnostic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-105X","authenticated-orcid":true,"given":"N. V.","family":"Vorokhobina","sequence":"additional","affiliation":[{"name":"North-Western State Medical University n.a. I.I. Mechnikov"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-7510","authenticated-orcid":true,"given":"E. S.","family":"Kozorezova","sequence":"additional","affiliation":[{"name":"National Clinical Center of Morphological Diagnostic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-2235","authenticated-orcid":true,"given":"F. A.","family":"Indeykin","sequence":"additional","affiliation":[{"name":"National Clinical Center of Morphological Diagnostic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-4056","authenticated-orcid":true,"given":"T. V.","family":"Savelyeva","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-5081","authenticated-orcid":true,"given":"I. V.","family":"Sleptsov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3001-664X","authenticated-orcid":true,"given":"R. A.","family":"Chernikov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-811X","authenticated-orcid":true,"given":"E. A.","family":"Fedorov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-0025","authenticated-orcid":true,"given":"A. A.","family":"Semenov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6986-1034","authenticated-orcid":true,"given":"I. K.","family":"Chinchuk","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3876-6306","authenticated-orcid":true,"given":"Sh. Sh.","family":"Shikhmagomedov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-5204","authenticated-orcid":true,"given":"M. A.","family":"Alekseev","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-0251","authenticated-orcid":true,"given":"L. M.","family":"Krasnov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-778X","authenticated-orcid":true,"given":"V. F.","family":"Rusakov","sequence":"additional","affiliation":[{"name":"Saint Petersburg State University, Saint Petersburg State University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Mel\u2019nichenko GA, Troshina EA, Bel\u2019tsevich DG, et al. Russian Association of Endocrinologists clinical practice guidelines for diagnosis and treatment of pheochromocytoma and paraganglioma. Endocrine Surgery. 2015;9(3):15-33. (In Russ.) doi: https:\/\/doi.org\/10.14341\/serg2015315-33","key":"ref1","DOI":"10.14341\/serg2015315-33"},{"doi-asserted-by":"crossref","unstructured":"Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. Sisli Etfal Hastan Tip Bul. 2020;54(2):159-168. doi: https:\/\/doi.org\/10.14744\/SEMB.2020.18794","key":"ref2","DOI":"10.14744\/SEMB.2020.18794"},{"doi-asserted-by":"crossref","unstructured":"Bancos I, Prete A. Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab. 2021;106(11):3331-3353. doi: https:\/\/doi.org\/10.1210\/clinem\/dgab512","key":"ref3","DOI":"10.1210\/clinem\/dgab512"},{"unstructured":"Lloyd RV, Osamura RY, Kloppel G, Rosai J, editors (2017). WHO Classification of Tumours of Endocrine Organs (4th edition). IARC: Lyon 2017","key":"ref4"},{"doi-asserted-by":"crossref","unstructured":"Lam A.K. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol. 2017;28:213\u2013227. doi: https:\/\/doi.org\/10.1007\/s12022-017-9484-5","key":"ref5","DOI":"10.1007\/s12022-017-9484-5"},{"doi-asserted-by":"crossref","unstructured":"Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathethic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96(3):717-725. doi: https:\/\/doi.org\/10.1210\/jc.2010-1946","key":"ref6","DOI":"10.1210\/jc.2010-1946"},{"doi-asserted-by":"crossref","unstructured":"Patel D, Phay JE, Yen TWF, et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine\/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Ann Surg Oncol. 2020;27(5):1329-1337. doi: https:\/\/doi.org\/10.1245\/s10434-020-08220-3","key":"ref7","DOI":"10.1245\/s10434-020-08220-3"},{"doi-asserted-by":"crossref","unstructured":"Goncalves J, Lussey-Lepoutre C, Favier J, et al. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. Ann Endocrinol (Paris). 2019;80:159-162. doi: https:\/\/doi.org\/10.1016\/j.ando.2019.04.003","key":"ref8","DOI":"10.1016\/j.ando.2019.04.003"},{"doi-asserted-by":"crossref","unstructured":"Bel\u2019tsevich D.G., Troshina E.A., Yukina M.Yu. Pheochromocytoma. Problems of endocrinology. (In Russ.) 2010;1:63-71","key":"ref9","DOI":"10.14341\/probl201056163-71"},{"unstructured":"Wang Y, Li M, Deng H, et al. The systems of metastatic potential prediction on pheochromocytoma and paraganglioma. Am J Cancer Res. 2020;10(3):769-780","key":"ref10"},{"doi-asserted-by":"crossref","unstructured":"Kostin AA, Vorobyev NV, Tolkachev AO, et al. Results of surgical treatment of adrenal lesions. Trials and practice in medicine. 2016;4(3):19-26 (In Russ.). doi: https:\/\/doi.org\/10.17709\/2409-2231-2016-3-4-2","key":"ref11","DOI":"10.17709\/2409-2231-2016-3-4-2"},{"doi-asserted-by":"crossref","unstructured":"Hamidi O, Young WF, Inguez-Ariza NM, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102(9):3296-3305. doi: https:\/\/doi.org\/10.1210\/jc.2017-00992","key":"ref12","DOI":"10.1210\/jc.2017-00992"},{"unstructured":"Kuz\u2019michev DE, Ilyina MP, Chirkov SV, Vil\u2019tsev IM. Clinical difficulties in diagnostic of pheochromocytoma. Medical expertise and law. 2014;3:56-57 (In Russ.)","key":"ref13"},{"unstructured":"Korotin AS, Kosheleva NA, Alkhimov AV, Rebrov AP. Features of the course of malignant pheochromocytoma. Clinical case. Kazan medical school diary. 2015;2(8):33-36 (In Russ.)","key":"ref14"},{"unstructured":"Bykov SV, Bykova NM, Schedreeva EL, Litvin MM. Case of malignant pheochromocytoma in old man. Siberian medical journal. 2002;30(1):80-82 (In Russ.)","key":"ref15"},{"doi-asserted-by":"crossref","unstructured":"Ishida E, Nakamura M, Shimada K, et al. Autopsy case prostate cancer with multiple endocrine neoplasia 2A. Pathol Int. 2004;54(12):918-23. doi: https:\/\/doi.org\/10.1111\/j.1440-1827.2004.01773.x","key":"ref16","DOI":"10.1111\/j.1440-1827.2004.01773.x"},{"doi-asserted-by":"crossref","unstructured":"Roman-Gonzalez A, Jimenez C. Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials. Curr Opin Endocrinol Diabetes Obes. 2017;24:174\u2013183. doi: https:\/\/doi.org\/10.1097\/MED.0000000000000330","key":"ref17","DOI":"10.1097\/MED.0000000000000330"},{"doi-asserted-by":"crossref","unstructured":"Plouin PF, Amar L, Dekkers OM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(5):G1-G10. doi: https:\/\/doi.org\/10.1530\/EJE-16-0033","key":"ref18","DOI":"10.1530\/EJE-16-0033"},{"doi-asserted-by":"crossref","unstructured":"Cho YY, Kwak MK, Lee SE, et al. A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score. Surgery. 2018;164(3):511-517. doi: https:\/\/doi.org\/10.1016\/j.surg.2018.05.001","key":"ref19","DOI":"10.1016\/j.surg.2018.05.001"},{"doi-asserted-by":"crossref","unstructured":"Zelinka T, Musil Z, Duskova J, et al. Metastatic pheochromocytoma: clinical, genetic, and histopathologic characteristics. Eur J Clin Invest. 2011;41(10):1121\u20131128. doi: https:\/\/doi.org\/10.1111\/j.1365-2362.2011.02518.x","key":"ref20","DOI":"10.1111\/j.1365-2362.2011.02518.x"},{"doi-asserted-by":"crossref","unstructured":"Szalat A, Fraenkel M, Doviner V, et al. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocr. 2011;39:160-166. doi: https:\/\/doi.org\/10.1007\/s12020-010-9422-5","key":"ref21","DOI":"10.1007\/s12020-010-9422-5"},{"doi-asserted-by":"crossref","unstructured":"Eisenhofer G, Lenders JW, Siegert G, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48:1739\u20131749. doi: https:\/\/doi.org\/10.1016\/j.ejca.2011.07.016","key":"ref22","DOI":"10.1016\/j.ejca.2011.07.016"},{"doi-asserted-by":"crossref","unstructured":"Stenman A, Svahn F, Hojjat-Farsangi M, et al. Molecular profiling of pheochromocytoma and abdominal paraganglioma stratified by the PASS algorithm reveals chromogranin b as associated with histologic prediction of malignant behavior. Am J Surg Pathol. 2019;43(3):409-421. doi: https:\/\/doi.org\/10.1097\/PAS.0000000000001190","key":"ref23","DOI":"10.1097\/PAS.0000000000001190"},{"doi-asserted-by":"crossref","unstructured":"August C, August K, Schroeder S, et al. CGH and CD 44\/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol. 2004;17(9):1119-28. doi: https:\/\/doi.org\/10.1038\/modpathol.3800160","key":"ref24","DOI":"10.1038\/modpathol.3800160"},{"doi-asserted-by":"crossref","unstructured":"Wailly P, Oragano L, Rade F, et al. Malignant pheochromocytoma: new malignancy criteria. Langenbecks Arch Surg. 2012;397:239-46. doi: https:\/\/doi.org\/10.1007\/s00423-011-0850-3","key":"ref25","DOI":"10.1007\/s00423-011-0850-3"},{"doi-asserted-by":"crossref","unstructured":"Agarwal A, Mehrotra PK, Jain M, et al. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg. 2010;34(12):3022-3028. doi: https:\/\/doi.org\/10.1007\/s00268-010-0744-5","key":"ref26","DOI":"10.1007\/s00268-010-0744-5"},{"doi-asserted-by":"crossref","unstructured":"Pierre C, Agopiantz M, Brunaud L, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the resk of metastasis and progression \u2013 free survival in pheochromocytomas\/paragangliomas. Virchows Arch. 2019;474(6):721-734. doi: https:\/\/doi.org\/10.1007\/s00428-019-02553-5","key":"ref27","DOI":"10.1007\/s00428-019-02553-5"},{"doi-asserted-by":"crossref","unstructured":"Kulkarini MM, Khandeparkar SGS, Deshmukh SD, et al. Stratification in paragangliomas with PASS (pheochromocytoma of the adrenal gland scaled score) and immunohistochemical markers. J Clin Diagn Res. 2016;10:EC01-EC04. doi: https:\/\/doi.org\/10.7860\/JCDR\/2016\/20565.8419.","key":"ref28","DOI":"10.7860\/JCDR\/2016\/20565.8419"},{"unstructured":"Unger P, et al. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch Pathol Lab Med. 1991;115:484-7","key":"ref29"},{"doi-asserted-by":"crossref","unstructured":"Bia\u0142as M OK, Dyduch G, Ciesielska-Milian K, et al. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study. Pol J Pathol. 2013;64: 129-135. doi: https:\/\/doi.org\/10.5114\/pjp.2013.36004","key":"ref30","DOI":"10.5114\/pjp.2013.36004"},{"doi-asserted-by":"crossref","unstructured":"Dahia PLM, Clifton-Bligh R, Gimenez-Roqueplo AP, et al. Hereditary endocrine tumours: current state-of-the-art and research opportunities: metastatic pheochromocytomas and paragangliomas- proceedings of the MEN2019 Symposium. Endocr Relat Cancer. 2020;27(8):t41-t52. doi: https:\/\/doi.org\/10.1530\/erc-19-0435","key":"ref31","DOI":"10.1530\/ERC-19-0435"},{"doi-asserted-by":"crossref","unstructured":"\u0420\u0435\u0431\u0440\u043e\u0432\u0430 \u0414.\u0412., \u0412\u043e\u0440\u043e\u0445\u043e\u0431\u0438\u043d\u0430 \u041d.\u0412., \u0418\u043c\u044f\u043d\u0438\u0442\u043e\u0432 \u0415.\u041d. \u0438 \u0434\u0440. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e-\u043b\u0430\u0431\u043e\u0440\u0430\u0442\u043e\u0440\u043d\u044b\u0435 \u043e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u043d\u0430\u0441\u043b\u0435\u0434\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u0444\u0435\u043e\u0445\u0440\u043e\u043c\u043e\u0446\u0438\u0442\u043e\u043c \u0438 \u043f\u0430\u0440\u0430\u0433\u0430\u043d\u0433\u043b\u0438\u043e\u043c \/\/ \u041f\u0440\u043e\u0431\u043b\u0435\u043c\u044b \u044d\u043d\u0434\u043e\u043a\u0440\u0438\u043d\u043e\u043b\u043e\u0433\u0438\u0438. 2022. \u2014 \u0422. 68. \u2014 \u21161. \u2014 \u0421. 8-17. doi: https:\/\/doi.org\/10.14341\/probl12834","key":"ref32","DOI":"10.14341\/probl12834"},{"doi-asserted-by":"crossref","unstructured":"Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92:3822\u20133828. doi: https:\/\/doi.org\/10.1210\/jc.2007-0709","key":"ref33","DOI":"10.1210\/jc.2007-0709"},{"doi-asserted-by":"crossref","unstructured":"Turkova H, Prodanov T, Maly M, et al. Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: An National Institutes of Health study. Endocr Pract. 2016;22:302\u2013314. doi: https:\/\/doi.org\/10.4158\/EP15725.OR","key":"ref34","DOI":"10.4158\/EP15725.OR"},{"doi-asserted-by":"crossref","unstructured":"Hescot S, Curras-Freixes M, Deutschbein T, et al. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors retrospective study. J Clin Endocrinol Metab. 2019;104:2367\u20132374. doi: https:\/\/doi.org\/10.1210\/jc.2018-01968","key":"ref35","DOI":"10.1210\/jc.2018-01968"},{"doi-asserted-by":"crossref","unstructured":"Richter S, Peitzsch M, Rapizzi E, et al. 2014 Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas\/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab. 2014;99:3903\u20133911. doi: https:\/\/doi.org\/10.1210\/jc.2014-2151","key":"ref36","DOI":"10.1210\/jc.2014-2151"},{"doi-asserted-by":"crossref","unstructured":"Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181-193. doi: https:\/\/doi.org\/10.1016\/j.ccell.2017.01.001","key":"ref37","DOI":"10.1016\/j.ccell.2017.01.001"},{"doi-asserted-by":"crossref","unstructured":"Granberg D, Juhlin CC, Falhammar H. Metastatic pheochromocytomas and abdominal paragangliomas. J Clin Endocrinol Metab. 2021;106(5):e1937-e1952. doi: https:\/\/doi.org\/10.1210\/clinem\/dgaa982","key":"ref38","DOI":"10.1210\/clinem\/dgaa982"},{"doi-asserted-by":"crossref","unstructured":"Muth A, Crona J, Gimm O, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med. 2019;285(2):187-204. doi: https:\/\/doi.org\/10.1111\/joim.12869","key":"ref39","DOI":"10.1111\/joim.12869"},{"doi-asserted-by":"crossref","unstructured":"Buffet A, Burnichon N, Amar L, Gimenez-Roqueplo AP. Pheochromocytoma: When to search a germline defect? Presse Med. 2018;47(7-8 Pt 2):e109-e118. doi: https:\/\/doi.org\/10.1016\/j.lpm.2018.07.003","key":"ref40","DOI":"10.1016\/j.lpm.2018.07.003"},{"doi-asserted-by":"crossref","unstructured":"Curr\u00e1s-Freixes M, Pi\u00f1eiro-Ya\u00f1ez E, Montero-Conde C, et al. PheoSeq: a targeted next-generation sequencing assay for pheochromocytoma and paraganglioma diagnostics. J Mol Diagn. 2017;19(4):575-588. doi: https:\/\/doi.org\/10.1016\/j.jmoldx.2017.04.009","key":"ref41","DOI":"10.1016\/j.jmoldx.2017.04.009"},{"doi-asserted-by":"crossref","unstructured":"Buffet A, Ben Aim L, Leboulleux S, et al. Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma. J Clin Endocrinol Metab. 2019;104(4):1109-1118. doi: https:\/\/doi.org\/10.1210\/jc.2018-02411","key":"ref42","DOI":"10.1210\/jc.2018-02411"},{"doi-asserted-by":"crossref","unstructured":"Brito JP, Asi N, Bancos I, et al. Testing for germline mutations in sporadic pheochromocytoma\/paraganglioma: a systematic review. Clin Endocrinol (Oxf). 2015;82(3):338-345. doi: https:\/\/doi.org\/10.1111\/cen.12530","key":"ref43","DOI":"10.1111\/cen.12530"},{"doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab. 2006;91(8):2851-2858. doi: https:\/\/doi.org\/10.1210\/jc.2005-2178","key":"ref44","DOI":"10.1210\/jc.2005-2178"},{"doi-asserted-by":"crossref","unstructured":"Thompson LDR. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26(5):551-66. doi: https:\/\/doi.org\/10.1097\/00000478-200205000-00002","key":"ref45","DOI":"10.1097\/00000478-200205000-00002"},{"doi-asserted-by":"crossref","unstructured":"Stenman A, Zedenius J, Juhlin CC. The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas \u2013 a meta-analysis and systematic review of the literature. Cancers. 2019;11:225-236. doi: https:\/\/doi.org\/10.3390\/cancers11020225","key":"ref46","DOI":"10.3390\/cancers11020225"},{"doi-asserted-by":"crossref","unstructured":"Baudin E, Habra MA, Deschamps F, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014;171:R111\u2013122. doi: https:\/\/doi.org\/10.1530\/EJE-14-0113","key":"ref47","DOI":"10.1530\/EJE-14-0113"},{"doi-asserted-by":"crossref","unstructured":"Kimura N, Takayanagi R, Takizawa N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21(3):405-414. doi: https:\/\/doi.org\/10.1530\/ERC-13-0494","key":"ref48","DOI":"10.1530\/ERC-13-0494"},{"doi-asserted-by":"crossref","unstructured":"Britvin TA, Motrenko AYu, Ilovayskaya IA, Gurevich LE. Clinical-and-lab and morphological predictors of pheochromocytoma progression. Tavric medicobiological vestnik. 2021;24(2):23-27 (In Russ.) doi: https:\/\/doi.org\/10.37279\/2070-8092-2021-24-2-23-27","key":"ref49","DOI":"10.1530\/endoabs.81.EP4"},{"doi-asserted-by":"crossref","unstructured":"Koh JM, Ahn SH, Kim H, et al. Validation of pathological grading systems from predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One. 2017;12(11):e0187398. doi: https:\/\/doi.org\/10.1371\/journal.pone.0187398","key":"ref50","DOI":"10.1371\/journal.pone.0187398"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13331\/10644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:19:20Z","timestamp":1716391160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5,20]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13331","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2023,10,4]]}}}